RTP Mobile Logo
Colorectal Cancer Update for Surgeons, Issue 1, 2009
Released November 2009

Featuring interviews with Drs Nicholas J Petrelli, Axel Grothey, Alan P Venook and John N Primrose. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Colorectal cancer (CRC) is one of the most rapidly evolving fields in oncology. Published results from a plethora of ongoing clinical trials lead to the continuous emergence of new therapeutic techniques, agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — surgeons caring for patients with CRC must be well informed of these advances. To bridge the gap between research and patient care, Colorectal Cancer Update for Surgeons utilizes one-on-one discussions with leading colorectal cancer investigators. By providing access to the latest research developments and expert perspectives, this CME program assists gastrointestinal surgeons in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Identify the strengths and weaknesses of genomic assays and clinicopathologic variables as tools for communicating risk of recurrence to patients with early colon cancer.
    • Formulate a treatment plan for patients with synchronous or metachronous, asymptomatic or symptomatic primary CRC and liver-only metastases.
    • Evaluate the pros and cons of perioperative versus postoperative systemic therapy for patients with resectable hepatic metastases.
    • Counsel patients receiving bevacizumab as part of perioperative or postoperative systemic therapy about potential treatment side effects, including surgical and wound-healing complications.
    • Recognize the significance of preexisting liver disease and comorbidities in the cumulative risk of steatohepatitis for patients receiving oxaliplatin or irinotecan.
    • Educate patients presenting with an asymptomatic primary tumor and synchronous metastatic CRC about their risk of requiring subsequent emergent surgery if they are treated with systemic therapy alone.
    • Summarize the effect of calcium and magnesium on the prevention or amelioration of oxaliplatin-associated sensory neurotoxicity or myalgias.
    • Counsel appropriately selected patients about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDrs Petrelli and Grothey had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr VenookAdvisory Committee: Bristol-Myers Squibb Company, ImClone Systems Incorporated; Paid Research: Bayer Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc. Prof PrimroseAdvisory Committee: Merck and Company Inc, Sanofi-Aventis; Speakers Bureau: Bayer Pharmaceuticals Corporation, Sanofi-Aventis.

    EDITORNeil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Merck and Company Inc, Millennium Pharmaceuticals Inc, Monogram Biosciences, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Wyeth.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.


    This program is supported by educational grants from Genentech BioOncology and Genomic Health Inc.


    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: November 2009
    Expiration date: November 2010

Acknowledge and close

Colorectal Cancer Update for Surgeons, Issue 1, 2009
Released November 2009

Featuring interviews with Drs Nicholas J Petrelli, Axel Grothey, Alan P Venook and John N Primrose. (Text and Audio Content)